ALX Oncology Holdings Inc. (ALXO)
$7.725
Rating:
Recommendation:
-
| Symbol | ALXO |
|---|---|
| Price | $7.725 |
| Beta | 1.719 |
| Volume Avg. | 0.16M |
| Market Cap | 317.898M |
| Shares () | - |
| 52 Week Range | 3.936-13.64 |
| 1y Target Est | - |
| DCF Unlevered | ALXO DCF -> | |
|---|---|---|
| DCF Levered | ALXO LDCF -> | |
| ROE | -122.89% | Strong Sell |
| ROA | -51.79% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 4.47% | Neutral |
| P/E | -2.42 | Sell |
| P/B | 1.48 | Strong Buy |
Latest ALXO news
About
Download (Excel)ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.